CTRI/2022/03/041181
Not yet recruiting
Phase 3
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety,Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults atHigh Risk of SARS-CoV-2 Exposure. - INNOVATE
Inovio Pharmaceuticals Inc0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Inovio Pharmaceuticals Inc
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Able to provide informed consent and have signed Informed Consent Form (ICF) prior to screening procedures;
- •2\.Men and non\-pregnant women 18 years of age or older;
- •3\.Per investigator judgment, healthy or stable with pre\-existing medical conditions that do not require significant change in medication or have led to a hospitalization in the 3 months prior to enrollment or who, in the judgment of the investigator, are unlikely to require a significant change in therapy or hospitalization for worsening disease through Day 56;
- •4\.Able and willing to comply with all study procedures;
- •5\.Working or residing in an environment with high risk of exposure to SARS\-CoV\-2 for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings. Examples include: 1\. Retail/service workers/educators (restaurant waitresses/waiters and bar workers, street vendors, store cashiers, hairdressers and barbers, veterinary staff, daycare workers, airport screening staff, school teachers and college professors teaching in\-person classes, college students attending in\-person classes, office workers and volunteers who have multiple brief exposures to people regularly) 2\. Factory workers (when working in confined settings with large numbers of employees, meat\-packing facilities) 3\. Drivers providing bus, taxi or shared ride services (e.g., Uber, Lyft) and delivery services 4\. User of public transportation (e.g., bus, train, subway) or public facilities (e.g. gyms) at least 3 times weekly 5\. Nursing home staff or correctional facility staff 6\. Retirement community residents or adult day program attendees who are regularly eating, socializing and/or exercising in common areas 7\. Person 51 years or older living in a multigenerational (at least 3 generations) household 8\. First responders (emergency medical technicians, police who are regularly assigned on patrol) Note: Firefighters typically use face shields and other protective gear but may be considered if they regularly assist with medical emergencies in the field 9\. Health care workers with prolonged patient interaction (includes nurses and nursing assistants, medical assistants and technicians, respiratory therapists, physical therapists, social workers, dentists and dental hygienists) 10\. Others, if in the opinion of the PI, the risk of COVID\-19 exposure is comparable to the examples above.
- •6\.Must meet one of the following criteria with respect to reproductive capacity: 1\. Women who are post\-menopausal as defined by reported spontaneous amenorrhea for \>\= 12 month; 2\. Surgically sterile or has a partner who is sterile (i.e., vasectomy in males or tubal ligation, absence of ovaries and/or uterus in females). In the case of vasectomy, subjects should wait six (6\) months post\-vasectomy prior to enrolling; 3\. Use of medically effective contraception with a failure rate of \< 1% per year when used consistently and correctly from screening until last dose. Acceptable methods include: i. hormonal contraception including implants, injections or oral; ii. two barrier methods, e.g., condom and cervical cap (with spermicide) or diaphragm (with spermicide); iii. intrauterine device or intrauterine system; iv. Abstinence when this is the subjectâ??s preferred and usual lifestyle. Note: Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post\-ovulation methods) and withdrawal are not acceptabl
Exclusion Criteria
- •1\.Acute febrile illness with temperature \>\= 100\.4°F (38\.0°C) or acute onset of upper or lower respiratory tract symptoms (e.g., cough, shortness of breath, sore throat) on Day 0 prior to dosing;
- •2\.Positive serologic test for SARS\-CoV\-2 at Screening (this criterion only applies after approximately 402 subjects positive for SARS\-CoV\-2 serologic test are randomized, after which this criterion will apply to all remaining subjects);
- •3\.Pregnant or breastfeeding, or intending to become pregnant or intending to father children starting from the Screening visit until the last dose;
- •4\.Positive urine pregnancy test during screening or immediately prior to dosing;
- •5\.Known history of uncontrolled HIV based on a CD4 count less than 200 cells/mm3 or a detectable viral load within 3 months prior to screening;
- •6\.Is currently participating or has participated in a study with an investigational product within 30 days prior to Day 0 (documented receipt of placebo in a previous trial would be permissible for trial eligibility);
- •7\.Previous or planned receipt of an investigational (including Emergency Use Authorization (EUA) or local equivalent authorization) or licensed vaccine for prevention or treatment of COVID\-19, MERS or SARS (documented receipt of placebo in previous trial would be permissible for trial eligibility);
- •8\.Immunosuppression as a result of underlying illness or treatment including:
- •a)Primary immunodeficiencies (conditions including hypothyroidism, Hashimotoâ??s thyroiditis and vitiligo are allowed);
- •b)Long term use (\>\=7 days) of oral or parenteral glucosteroids at a dose of \>\=20 mg/day of prednisone equivalent (use of inhaled, topical, nasal, otic, and ophthalmic corticosteroids are allowed) in the past 6 months;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVRespiratory Syncytial VirusMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002023-11-HUJanssen-Cilag International NV737
Active, not recruiting
Phase 1
Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone.EUCTR2014-005153-39-LTexicon Pharmaceuticals, Inc.750
Active, not recruiting
Phase 1
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVEUCTR2020-002023-11-SEJanssen-Cilag International NV737
Active, not recruiting
Phase 1
A Study of the Effects of AMG 334 to Prevent Migraine HeadachesEUCTR2014-004464-38-NLAmgen Inc852
Active, not recruiting
Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)Immunoglobulin A Nephropathy (IgAN)Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2020-003084-26-CZChinook Therapeutics U.S., Inc.320